NEUEHEALTH INC (NEUE) Fundamental Analysis & Valuation

NYSE:NEUE • US10920V4041

Current stock price

6.753 USD
+0.08 (+1.24%)
At close:
6.73 USD
-0.02 (-0.34%)
Pre-Market:

This NEUE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NEUE Profitability Analysis

1.1 Basic Checks

  • In the past year NEUE has reported negative net income.
  • NEUE had a negative operating cash flow in the past year.
  • NEUE had negative earnings in each of the past 5 years.
  • In multiple years NEUE reported negative operating cash flow during the last 5 years.
NEUE Yearly Net Income VS EBIT VS OCF VS FCFNEUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

  • The Return On Assets of NEUE (-18.13%) is worse than 81.19% of its industry peers.
Industry RankSector Rank
ROA -18.13%
ROE N/A
ROIC N/A
ROA(3y)-54.73%
ROA(5y)-42.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUE Yearly ROA, ROE, ROICNEUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NEUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUE Yearly Profit, Operating, Gross MarginsNEUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NEUE Health Analysis

2.1 Basic Checks

  • NEUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEUE has been increased compared to 1 year ago.
  • The number of shares outstanding for NEUE has been increased compared to 5 years ago.
  • The debt/assets ratio for NEUE is higher compared to a year ago.
NEUE Yearly Shares OutstandingNEUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NEUE Yearly Total Debt VS Total AssetsNEUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • NEUE has an Altman-Z score of -6.94. This is a bad value and indicates that NEUE is not financially healthy and even has some risk of bankruptcy.
  • NEUE has a Altman-Z score of -6.94. This is amonst the worse of the industry: NEUE underperforms 91.09% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.94
ROIC/WACCN/A
WACC6%
NEUE Yearly LT Debt VS Equity VS FCFNEUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B

2.3 Liquidity

  • A Current Ratio of 2.70 indicates that NEUE has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.70, NEUE belongs to the top of the industry, outperforming 83.17% of the companies in the same industry.
  • A Quick Ratio of 2.70 indicates that NEUE has no problem at all paying its short term obligations.
  • NEUE's Quick ratio of 2.70 is amongst the best of the industry. NEUE outperforms 83.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
NEUE Yearly Current Assets VS Current LiabilitesNEUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NEUE Growth Analysis

3.1 Past

  • NEUE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.23%.
  • The Revenue for NEUE has decreased by -13.83% in the past year. This is quite bad
  • NEUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.26% yearly.
EPS 1Y (TTM)-87.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.89%
Revenue 1Y (TTM)-13.83%
Revenue growth 3Y-14.76%
Revenue growth 5Y27.26%
Sales Q2Q%-7.48%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.62% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 16.81% on average over the next years. This is quite good.
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NEUE Yearly Revenue VS EstimatesNEUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NEUE Yearly EPS VS EstimatesNEUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. NEUE Valuation Analysis

4.1 Price/Earnings Ratio

  • NEUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NEUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUE Price Earnings VS Forward Price EarningsNEUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUE Per share dataNEUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.62%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NEUE Dividend Analysis

5.1 Amount

  • NEUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUE Fundamentals: All Metrics, Ratios and Statistics

NEUEHEALTH INC

NYSE:NEUE (10/1/2025, 9:16:12 PM)

Premarket: 6.73 -0.02 (-0.34%)

6.753

+0.08 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07
Earnings (Next)11-05
Inst Owners51.44%
Inst Owner ChangeN/A
Ins Owners11.99%
Ins Owner Change-786.68%
Market Cap60.91M
Revenue(TTM)890.44M
Net Income(TTM)-134.80M
Analysts42.86
Price Target7.14 (5.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.36%
Min EPS beat(2)61.7%
Max EPS beat(2)111.02%
EPS beat(4)3
Avg EPS beat(4)55.87%
Min EPS beat(4)-23.97%
Max EPS beat(4)111.02%
EPS beat(8)4
Avg EPS beat(8)68.26%
EPS beat(12)6
Avg EPS beat(12)40.72%
EPS beat(16)6
Avg EPS beat(16)0.91%
Revenue beat(2)0
Avg Revenue beat(2)-31.77%
Min Revenue beat(2)-33.05%
Max Revenue beat(2)-30.49%
Revenue beat(4)0
Avg Revenue beat(4)-18.95%
Min Revenue beat(4)-33.05%
Max Revenue beat(4)-2.77%
Revenue beat(8)1
Avg Revenue beat(8)-12.15%
Revenue beat(12)2
Avg Revenue beat(12)-15.49%
Revenue beat(16)2
Avg Revenue beat(16)-38.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.16
EYN/A
EPS(NY)-14.9
Fwd EYN/A
FCF(TTM)-8.23
FCFYN/A
OCF(TTM)-7.77
OCFYN/A
SpS98.72
BVpS-49.75
TBVpS-57.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.73%
ROA(5y)-42.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.87%
Cap/Sales 0.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z -6.94
F-Score4
WACC6%
ROIC/WACCN/A
Cap/Depr(3y)27.02%
Cap/Depr(5y)49%
Cap/Sales(3y)0.54%
Cap/Sales(5y)0.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.89%
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.83%
Revenue growth 3Y-14.76%
Revenue growth 5Y27.26%
Sales Q2Q%-7.48%
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y81.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year152.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.24%
OCF growth 3YN/A
OCF growth 5YN/A

NEUEHEALTH INC / NEUE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NEUEHEALTH INC?

ChartMill assigns a fundamental rating of 2 / 10 to NEUE.


Can you provide the valuation status for NEUEHEALTH INC?

ChartMill assigns a valuation rating of 0 / 10 to NEUEHEALTH INC (NEUE). This can be considered as Overvalued.


How profitable is NEUEHEALTH INC (NEUE) stock?

NEUEHEALTH INC (NEUE) has a profitability rating of 0 / 10.


How financially healthy is NEUEHEALTH INC?

The financial health rating of NEUEHEALTH INC (NEUE) is 3 / 10.


What is the earnings growth outlook for NEUEHEALTH INC?

The Earnings per Share (EPS) of NEUEHEALTH INC (NEUE) is expected to grow by 14% in the next year.